Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab
- PMID: 17058279
- DOI: 10.1002/ppul.20507
Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab
Abstract
A population-based study of the impact of palivizumab on confirmed Respiratory Syncytial Virus (RSV) hospitalizations over a 7-year period within and between two similar health regions . Clinicians in Calgary implemented palivizumab prophylaxis for high-risk infants during the last four RSV seasons; clinicians in Edmonton did not. The two cities are part of a unified health care system and similar sociodemographics. Infants <36 weeks (wk) of gestational age (GA) were identified. RSV prophylaxis data and RSV-hospitalizations for high-risk infants eligible for prophylaxis were reviewed, as well as that of moderate-risk infants (33-35 weeks GA) for whom RSV prophylaxis was not given a high priority in the recommendations published by the Canadian Paediatric Society (CPS). Prevalence of RSV hospitalization before and after palivizumab was determined (1995-1998 and 1999-2002, respectively). There were 411 high-risk infants eligible for palivizumab prior to its provision (Pre) and 496 during the prophylaxis program (Post) in Calgary. There were 401 Pre and 425 Post in Edmonton, where no such prophylaxis program was implemented. In Calgary where palivizumab was offered (Post), RSV hospitalization was significantly reduced: 7.3% Pre versus 3.0% Post (OR, 2.53, 95% CI, 1.34, 4.76). No reduction was observed in Edmonton where palivizumab was not offered: 5.0% Pre versus 7.1% Post (OR, 1.45, 95% CI, 0.81, 2.59; P = 0.212). RSV hospitalizations did not change for moderate-risk infants not receiving palivizumab in Calgary (OR, 1.26, 95% CI, 0.75, 2.12; P = 0.389). An RSV prevention program with palivizumab for high-risk infants reduced RSV hospitalizations, providing "real life" evidence of the benefits of this prophylaxis strategy. Further research is required to determine if specific sub-sets of moderate-risk infants would also benefit from an RSV prophylaxis program with palivizumab.
Similar articles
-
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.Pediatrics. 1998 Sep;102(3 Pt 1):531-7. Pediatrics. 1998. PMID: 9738173 Clinical Trial.
-
Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.Curr Med Res Opin. 2009 Jul;25(7):1585-91. doi: 10.1185/03007990902929112. Curr Med Res Opin. 2009. PMID: 19469698
-
Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.Pediatr Infect Dis J. 2004 Jan;23(1):27-31. doi: 10.1097/01.inf.0000105106.93562.d3. Pediatr Infect Dis J. 2004. PMID: 14743042
-
Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?Clin Ther. 2004 Dec;26(12):2130-7. doi: 10.1016/j.clinthera.2004.12.005. Clin Ther. 2004. PMID: 15823776 Review.
-
[Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].Klin Padiatr. 1999 Nov-Dec;211(6):450-5. doi: 10.1055/s-2008-1043832. Klin Padiatr. 1999. PMID: 10592925 Review. German.
Cited by
-
Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks' Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study.J Pediatric Infect Dis Soc. 2021 Apr 3;10(3):237-244. doi: 10.1093/jpids/piaa046. J Pediatric Infect Dis Soc. 2021. PMID: 32530035 Free PMC article.
-
Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis.Eur J Clin Microbiol Infect Dis. 2017 Jun;36(6):1057-1062. doi: 10.1007/s10096-016-2891-6. Epub 2017 Jan 11. Eur J Clin Microbiol Infect Dis. 2017. PMID: 28078558 Free PMC article.
-
Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012.PLoS One. 2016 Apr 6;11(4):e0152208. doi: 10.1371/journal.pone.0152208. eCollection 2016. PLoS One. 2016. PMID: 27050095 Free PMC article.
-
Preventing hospitalizations for respiratory syncytial virus infection.Paediatr Child Health. 2015 Aug-Sep;20(6):321-33. doi: 10.1093/pch/20.6.321. Paediatr Child Health. 2015. PMID: 26435673 Free PMC article.
-
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective.Int J Pediatr. 2014;2014:571609. doi: 10.1155/2014/571609. Epub 2014 Dec 4. Int J Pediatr. 2014. PMID: 25548575 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical